Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16472
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Murphy, C | - |
dc.contributor.author | Hawkes, E | - |
dc.contributor.author | Chionh, Fiona | - |
dc.contributor.author | Chong, Geoff | - |
dc.date | 2016-10-28 | - |
dc.date.accessioned | 2017-01-02T23:13:36Z | - |
dc.date.available | 2017-01-02T23:13:36Z | - |
dc.date.issued | 2017-02 | - |
dc.identifier.citation | Journal of Clinical Pharmacy and Therapeutics 2017; 42(1): 111-114 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16472 | - |
dc.description.abstract | WHAT IS KNOWN AND OBJECTIVE: Human herpesvirus-8 (HHV-8)-positive, HIV-negative multicentric Castleman's disease is a rare lymphoproliferative disorder with no standardized treatment. Concurrent Kaposi's sarcoma, another HHV-8-related disease, is uncommon in HIV-negative patients. The role of antiviral therapy and rituximab in HIV-negative patients is not well established. CASE DESCRIPTION: We report a case of a 5-year, durable remission of HHV-8-positive, HIV-negative comorbid multicentric Castleman's disease and Kaposi's sarcoma treated with long-term valganciclovir, following initial rituximab and liposomal doxorubicin. WHAT IS NEW AND CONCLUSION: Currently, there is no defined role for antiviral therapy in the treatment of HIV-negative HHV-8-positive multicentric Castleman's disease and Kaposi's sarcoma. Ganciclovir followed by indefinite, continuous valganciclovir is thought to have contributed significantly to the durable response in this case. | en_US |
dc.subject | Kaposi's sarcoma | en_US |
dc.subject | Human herpesvirus-8 | en_US |
dc.subject | Multicentric Castleman's disease | en_US |
dc.subject | Valganciclovir | en_US |
dc.title | Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Journal of Clinical Pharmacy and Therapeutics | en_US |
dc.identifier.affiliation | Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia | en_US |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia | en_US |
dc.type.studyortrial | Case Series and Case Reports | en_US |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/27790727 | en_US |
dc.identifier.doi | 10.1111/jcpt.12472 | en_US |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en_US |
local.name.researcher | Hawkes, Eliza A | |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Clinical Haematology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.